ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO249

Comparison of Tacrolimus and Mycophenolate Mofetil for Induction of Remission in Lupus Nephritis in Thailand: A Multicenter Randomized Controlled Trial

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Ophascharoensuk, Vuddhidej, Chiang Mai University, Chiang Mai, Thailand
  • Ingsathit, Atiporn, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • Anutrakulchai, Sirirat, Khon Kaen University, Khon Kaen, Thailand
  • Avihingsanon, Yingyos, King Chulalongkorn Memorial hospital, Chulalongkorn University, Bangkok, Thailand
  • Chawanasuntorapoj, Ratana, Siriraj Hospital, Bangkok, Thailand
  • Sangthawan, Pornpen, Prince of Songkla University Hospital, Songkhla, Thailand
  • Kasitanon, Nuntana, Chiang Mai University, Chiang Mai, Thailand
  • Pichaiwong, Warangkana, RAJAVITHI HOSPITAL, Bangkok, Thailand
  • Ngamjanyaporn, Pintip, Ramathibodi Hospital, Bangkok, Thailand
  • Sumethkul, Vasant, Ramathibodi Hospital, Bangkok, Thailand

Group or Team Name

  • warangkana

We conducted a prospective multi-center, opened-label, parallel, randomized, controlled trial to compare tacrolimus (TAC) and mycophenolate mofetil (MMF) for induction of remission in lupus nephritis (LN).


Adult patients with biopsy-proven LN ISN/RPS Class III-V and active nephritis were receive prednisolone (0.7-1.0 mg/kg/day for 4 weeks of run in period and tapered) and randomly assigned to receive TAC (0.1 mg/kg/day) or MMF (1.5–2 g/day) for 6 months. All patients who had remission received AZA 1-2 mg/kg/day as standard treatment in the maintenance phase. The primary outcome was the probability of complete remission (CR) at 6 and 12 months and the secondary outcomes included CR or partial remission (PR), renal parameter (UPCR, serum creatinine, and GFR), adverse events (infection, leukopenia, GI symptoms, new onset DM/hyperglycemia, and alopecia) and health related quality of life scores (EQ5D).


84 patients were randomized. One patient who was randomized to TAC group withdrew from the study immediately after randomization. Therefore, 42 patients were received MMF and 41 patients were received TAC.
Median times to complete remission were 6.1 months and 5.1 months in MMF and TAC groups (P= 0.82). The probability of CR was similar between 2 groups (HR=0.99; 95%CI 0.53 to 1.85; P=0.97). The reduction in UPCR were similar between 2 groups during induction period but there were significantly increasing UPCR in TAC group at 12 months (P=0.03). There were worsening serum creatinine and GFR in TAC group compared with MMF group during induction period but both serum creatinine and GFR were similar after maintenance therapy. Infection occurred more frequently in MMF group. Other adverse events and EQ5D scores were similar between 2 groups.


TAC is effective as MMF for induction therapy of active LN class III-IV. It have less infections than MMF but transiently increased serum creatinine and decreased GFR compared with MMF. ID: NCT01580865


  • Commercial Support